Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.
Ann Surg. 2024 May 1;279(5):808-817. doi: 10.1097/SLA.0000000000006215. Epub 2024 Jan 24.
To compare the short-term and long-term outcomes between robotic gastrectomy (RG) and laparoscopic gastrectomy (LG) for gastric cancer.
The clinical outcomes of RG over LG have not yet been effectively demonstrated.
This retrospective cohort study included 3599 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals in China from January 2015 to June 2019. Propensity score matching was performed between patients who received RG and LG. The primary end point was 3-year disease-free survival (DFS).
After 1:1 propensity score matching, 1034 pairs of patients were enrolled in a balanced cohort for further analysis. The 3-year DFS in the RG and LG was 83.7% and 83.1% ( P =0.745), respectively, and the 3-year overall survival was 85.2% and 84.4%, respectively ( P =0.647). During 3 years of follow-up, 154 patients in the RG and LG groups relapsed (cumulative incidence of recurrence: 15.0% vs 15.0%, P =0.988). There was no significant difference in the recurrence sites between the 2 groups (all P >0.05). Sensitivity analysis showed that RG had comparable 3-year DFS (77.4% vs 76.7%, P =0.745) and overall survival (79.7% vs 78.4%, P =0.577) to LG in patients with advanced (pathologic T2-4a) disease, and the recurrence pattern within 3 years was also similar between the 2 groups (all P >0.05). RG had less intraoperative blood loss, lower conversion rate, and shorter hospital stays than LG (all P >0.05).
For resectable gastric cancer, including advanced cases, RG is a safe approach with comparable 3-year oncological outcomes to LG when performed by experienced surgeons.
比较机器人胃切除术(RG)与腹腔镜胃切除术(LG)治疗胃癌的短期和长期疗效。
RG 相较于 LG 的临床疗效尚未得到有效证实。
本回顾性队列研究纳入了 2015 年 1 月至 2019 年 6 月在中国 8 家高容量医院接受根治性胃切除术的 3599 例胃癌患者。对接受 RG 和 LG 的患者进行倾向评分匹配。主要终点是 3 年无病生存率(DFS)。
经过 1:1 倾向评分匹配,纳入了 1034 对患者进行平衡队列分析。RG 和 LG 组的 3 年 DFS 分别为 83.7%和 83.1%(P=0.745),3 年总生存率分别为 85.2%和 84.4%(P=0.647)。在 3 年随访期间,RG 和 LG 组分别有 154 例患者复发(累积复发率:15.0%比 15.0%,P=0.988)。两组的复发部位无显著差异(均 P>0.05)。敏感性分析显示,对于进展期(病理 T2-4a 期)疾病患者,RG 的 3 年 DFS(77.4%比 76.7%,P=0.745)和总生存率(79.7%比 78.4%,P=0.577)与 LG 相当,且 3 年内的复发模式也相似(均 P>0.05)。RG 组术中出血量更少、中转开腹率更低、住院时间更短(均 P>0.05)。
对于可切除的胃癌,包括进展期病例,由经验丰富的外科医生施行时,RG 是一种安全的方法,其 3 年肿瘤学结果与 LG 相当。